EUVIMEDEUVIMED entdecken
Crossref

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing

Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M Haikala, Olli Kallioniemi, Mikko I Mäyränpää, Ilkka Ilonen

Lung Cancer · 2023

DOI: 10.1016/j.lungcan.2023.02.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung Cancer, 2023. Verfasst von Hely Ollila-Raj und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Institute for Mo…. Hauptthemen laut MEDLINE: Lung Neoplasms, Mesothelioma, Malignant, Mesothelioma, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Pleural mesothelioma (PM) is an aggressive malignancy with limited treatment options. The first-line therapy has remained unchanged for two decades and consists of pemetrexed in combination with cisplatin. Immune-checkpoint inhibitors (nivolumab plus ipilimumab) have high response rates, resulting in recent updates in treatment recommendations by the U.S. Food and Drug Administration. However, the overall benefits of combination treatment are modest, suggesting that other targeted therapy options should be investigated. MATERIALS AND METHODS: We employed high-throughput drug sensitivity and resistance testing on five established PM cell lines using 527 cancer drugs in a 2D setting. Drugs of the greatest potential (n = 19) were selected for further testing in primary cell models derived from pleural effusions of seven PM patients. RESULTS: All established and primary patient-derived PM cell models were sensitive to the mTOR inhibitor AZD8055. Furthermore, another mTOR inhibitor (temsirolimus) showed efficacy in most of the primary patient-derived cells, although a less robust effect was observed when compared with the established cell lines. Most of the established cell lines and all patient-derived primary cells exhibited sensitivity to the PI3K/mTOR/DNA-PK inhibitor LY3023414. The Chk1 inhibitor prexasertib showed activity in 4/5 (80%) of the established cell lines and in 2/7 (29%) of the patient-derived primary cell lines. The BET family inhibitor JQ1 showed activity in four patient-derived cell models and in one established cell line. CONCLUSION: mTOR and Chk1 pathways had promising results with established mesothelioma cell lines in an ex vivo setting. In patient-derived primary cells, drugs targeting mTOR pathway in particular showed efficacy. These findings may inform novel treatment strategies for PM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMesothelioma, MalignantMesotheliomaAntineoplastic AgentsPleural NeoplasmsHumansPharmaceutical PreparationsMTOR InhibitorsTOR Serine-Threonine KinasesCell Line, Tumor

Stichwörter der Autor:innen

Drug sensitivity testingPleural mesotheliomaPrexasertibmTOR inhibitors

Substanzen

Pharmaceutical PreparationsMTOR InhibitorsAntineoplastic AgentsTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (H…
  • Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Finland.
  • Department of Pulmonary Medicine, Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Finland.
  • Radiology, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Finland.
  • Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Finland; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska I…

Zitieren

APA

Ollila-Raj, H., Murumägi, A., Pellinen, T., Arjama, M., Sutinen, E., Volmonen, K., Haikala, H. M., Kallioniemi, O., Mäyränpää, M. I., & Ilonen, I. (2023). Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing. Lung Cancer. https://doi.org/10.1016/j.lungcan.2023.02.024

Vancouver

Ollila-Raj H, Murumägi A, Pellinen T, Arjama M, Sutinen E, Volmonen K, et al. Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing. Lung Cancer. 2023. doi:10.1016/j.lungcan.2023.02.024

BibTeX
@article{OllilaRaj2023,
  author = {Ollila-Raj, Hely and Murumägi, Astrid and Pellinen, Teijo and Arjama, Mariliina and Sutinen, Eva and Volmonen, Kirsi and Haikala, Heidi M and Kallioniemi, Olli and Mäyränpää, Mikko I and Ilonen, Ilkka},
  title = {Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing},
  journal = {Lung Cancer},
  year = {2023},
  doi = {10.1016/j.lungcan.2023.02.024}
}
Kostenlos starten →